• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Eunice L. Kwak, MD, PhD

Publications

  • Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-Del Castillo C, Ryan DP, Hong TS.FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience.Oncologist. 2013 May 8.
    23657686
  • Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.Oncologist. 2013 Apr 11.
    23580238
  • Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC.Preoperative cetuximab, irinotecan, Cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.Oncologist. 2013;18(3):281-7.
    23429739
  • Hong TS, Wo JY, Kwak EL.Targeted therapies with chemoradiation in esophageal cancer: development and future directions.Semin Radiat Oncol. 2013 Jan;23(1):31-7.
    23207045
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012 Oct;13(10):1011-9.
    22954507
  • Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Fernandez-Del Castillo C, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR.Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a "True" R0 Resection?.Ann Surg. 2012 Sep 10.
    22968073
  • Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ.Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.J Clin Oncol. 2012 Jul 1;30(19):2348-53.
    22529266
  • Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI.Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.Clin Cancer Res. 2011 Feb 15;17(4):849-60.
    21131552
  • Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, Delaney TF, Fernandez-Del Castillo C.Phase I Study of Preoperative Short-Course Chemoradiation with Proton Beam Therapy and Capecitabine for Resectable Pancreatic Ductal Adenocarcinoma of the Head.Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):151-7.
    20421151
  • Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ.Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.J Thorac Oncol. 2010 Dec;5(12):2044-6.
    21102269
  • Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS.Dose-painted Intensity-modulated Radiation Therapy for Anal Cancer: A Multi-institutional Report of Acute Toxicity and Response to Therapy.Int J Radiat Oncol Biol Phys. 2010 Nov 20.
    21095071
  • Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med. 2010 Oct 28;363(18):1727-33.
    20979472
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.EMBO Mol Med. 2010 May;2(5):146-58.
    20432502
  • Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV.Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.Lancet Oncol. 2010 Jan;11(1):48-54.
    19932054
  • Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK.J Clin Oncol. 2009 Sep 10;27(26):4247-53.
    19667264
  • Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA.Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.Br J Cancer. 2009 Aug 4;101(3):465-72.
    19603024
  • Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK.Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study.J Clin Oncol. 2009 Jun 20;27(18):3027-35.
    19470923
  • Kwak EL, Hong TS, Berger DL, Forcione DG, Uppot RN, Lauwers GY.Case records of the Massachusetts General Hospital. Case 19-2009. A 63-year-old woman with carcinoma of the gastroesophageal junction.N Engl J Med. 2009 Jun 18;360(25):2656-64.
    19535805
  • Figlin RA,Brown E,Armstrong AJ,Akerley W,Benson AB 3rd,Burstein HJ,Ettinger DS,Febbo PG,Fury MG,Hudes GR,Kies MS,Kwak EL,Morgan RJ Jr,Mortimer J,Reckamp K,Venook AP,Worden F,Yen Y.NCCN Task Force Report: mTOR inhibition in solid tumors.J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-S20; quiz S21-S22. Review.
    18926092
  • Asomaning K,Reid AE,Zhou W,Heist RS,Zhai R,Su L,Kwak EL,Blaszkowsky L,Zhu AX,Ryan DP,Christiani DC,Liu G.MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.Clin Cancer Res. 2008 Jun 15;14(12):4010-5.
    18559624
  • Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature. 2007 Dec 20;450(7173):1235-9.
    18097410
  • Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.J Clin Oncol. 2007 Oct 20;25(30):4787-92.
    17947726
  • Kwak EL, Clark JW, Chabner B.Targeted agents: the rules of combination.Clin Cancer Res. 2007 Sep 15;13(18):5232-7. Review.
    17875749
  • Hipp J, Andersson KE, Kwon TG, Kwak EK, Yoo J, Atala A.Microarray analysis of exstrophic human bladder smooth muscle.BJU Int. 2008 Jan;101(1):100-5.
    17868416
  • Kwak EL, Chung DC.Hereditary colorectal cancer syndromes: an overview.Clin Colorectal Cancer. 2007 Jan;6(5):340-4. Review.
    17311698
  • Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J.Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.Cold Spring Harb Symp Quant Biol. 2005;70:419-26. Review.
    16869779
  • Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW.Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7.
    16857803
  • Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA.Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.Cancer Res. 2006 Feb 15;66(4):1923-8.
    16488990
  • Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW.Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.Gynecol Oncol. 2005 Jul;98(1):124-8.
    15913747
  • Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70.
    15897464